A Study of LY3305677 in Healthy Participants

Inclusion criteria

• Overtly healthy as determined by medical history and physical examination
• Male participants: will agree to use a reliable method of birth control and will not donate sperm during the study and for at least 3 months following the last dose of the investigational product
• Female participants: women not of child-bearing potential due to surgical sterilization confirmed by medical history or menopause
• First generation Japanese participants or non-Japanese participants
• Have a body weight of more than 50 kilograms (kg)

Exclusion criteria

• Have participated within the last 3 months in a clinical trial involving an investigational product
• Have known allergies to glucagon-like peptide-1 (GLP-1) analogs, or any components of the formulation, or history of significant atopy
• Have an abnormality in the 12-lead electrocardiogram (ECG) at screening and/or Day -1
• Have undergone any form of bariatric surgery
• Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis
• Have a history of acute or chronic pancreatitis or elevation in serum lipase and/or amylase
• Show evidence of human immunodeficiency virus (HIV) or Hepatitis B or C
• Have used or intend to use medications that promote weight loss
• Have donated blood of more than 500 milliliter (mL) within the last month
• Currently smoke more than 10 cigarettes per day